Javascript must be enabled to continue!
De-novo promoters emerge more readily from random DNA than from genomic DNA
View through CrossRef
Abstract
Promoters are DNA sequences that help to initiate transcription. Point mutations can create de-novo promoters, which can consequently transcribe inactive genes or create novel transcripts. We know little about how de-novo promoters emerge in genomic DNA, especially compared to random DNA that has never been subjected to selection. Here, we assayed the promoter activity of 17,129 random, synthetic DNA sequences and 91,866 E. coli genomic DNA sequences. Genomic DNA encodes ~1.3 times more promoters than random DNA. We then studied 584,573 point mutations in 225 random and 60 genomic sequences, and asked how they cause the emergence of de-novo promoters. We find that de-novo promoters emerge ~3 times more readily from random DNA than from genomic DNA. The reason is that the genome contains fewer proto-binding sites for transcriptional activators than random DNA. Our work shows that the evolutionary history of a DNA sequence introduces substantial biases in its evolutionary potential, especially in the likelihood that mutations create new and potentially adaptive transcripts.
Title: De-novo promoters emerge more readily from random DNA than from genomic DNA
Description:
Abstract
Promoters are DNA sequences that help to initiate transcription.
Point mutations can create de-novo promoters, which can consequently transcribe inactive genes or create novel transcripts.
We know little about how de-novo promoters emerge in genomic DNA, especially compared to random DNA that has never been subjected to selection.
Here, we assayed the promoter activity of 17,129 random, synthetic DNA sequences and 91,866 E.
coli genomic DNA sequences.
Genomic DNA encodes ~1.
3 times more promoters than random DNA.
We then studied 584,573 point mutations in 225 random and 60 genomic sequences, and asked how they cause the emergence of de-novo promoters.
We find that de-novo promoters emerge ~3 times more readily from random DNA than from genomic DNA.
The reason is that the genome contains fewer proto-binding sites for transcriptional activators than random DNA.
Our work shows that the evolutionary history of a DNA sequence introduces substantial biases in its evolutionary potential, especially in the likelihood that mutations create new and potentially adaptive transcripts.
Related Results
Genome wide hypomethylation and youth-associated DNA gap reduction promoting DNA damage and senescence-associated pathogenesis
Genome wide hypomethylation and youth-associated DNA gap reduction promoting DNA damage and senescence-associated pathogenesis
Abstract
Background: Age-associated epigenetic alteration is the underlying cause of DNA damage in aging cells. Two types of youth-associated DNA-protection epigenetic mark...
Echinococcus granulosus in Environmental Samples: A Cross-Sectional Molecular Study
Echinococcus granulosus in Environmental Samples: A Cross-Sectional Molecular Study
Abstract
Introduction
Echinococcosis, caused by tapeworms of the Echinococcus genus, remains a significant zoonotic disease globally. The disease is particularly prevalent in areas...
iPromoter-Seqvec: identifying promoters using bidirectional long short-term memory and sequence-embedded features
iPromoter-Seqvec: identifying promoters using bidirectional long short-term memory and sequence-embedded features
Abstract
Background
Promoters, non-coding DNA sequences located at upstream regions of the transcription start site of genes/gene clusters, are esse...
The Location of Genomic Breakpoints in AML1/RUNX1 and ETO in De Novo znd Therapy-Related Leukemia Patients sith T(8;21) Are Similar znd Colocalize with Topoisomerase II Cleavage Sites.
The Location of Genomic Breakpoints in AML1/RUNX1 and ETO in De Novo znd Therapy-Related Leukemia Patients sith T(8;21) Are Similar znd Colocalize with Topoisomerase II Cleavage Sites.
Abstract
The t(8;21)(q22;q22) that results in an AML1-ETO fusion gene is frequently detected in de novo and in therapy-related acute myeloid leukemia (AML) patients....
12481 Evaluating The Device Handling And Preference Assessment Questionnaire For Growth Hormone Deficiency: Results From Content Validation Interviews
12481 Evaluating The Device Handling And Preference Assessment Questionnaire For Growth Hormone Deficiency: Results From Content Validation Interviews
Abstract
Disclosure: J. Neergaard: Employee; Self; Novo Nordisk. S. Akhtar: Employee; Self; Novo Nordisk. Stock Owner; Self; Novo Nordisk. B. Berg: Employee; Self; N...
Modulating Fis and IHF binding specificity, crosstalk and regulatory logic through the engineering of complex promoters
Modulating Fis and IHF binding specificity, crosstalk and regulatory logic through the engineering of complex promoters
AbstractBacterial promoters are usually formed by multiplecis-regulatory elements recognized by a plethora of transcriptional factors (TFs). From those, global regulators are key e...
1651-P: Elevated FGF21 Levels after Total Pancreatectomy and in Response to Single-Dose Glucagon Receptor Antagonism in Humans
1651-P: Elevated FGF21 Levels after Total Pancreatectomy and in Response to Single-Dose Glucagon Receptor Antagonism in Humans
Fibroblast growth factor 21 (FGF21) is a liver-secreted peptide hormone reportedly improving metabolic homeostasis, partly via reduced hunger for sugar, fat, protein and alcohol. E...
Yuk Ming Dennis Lo
Yuk Ming Dennis Lo
A propósito do artigo sobre a trissomia 21, incluído neste número da Gazeta Médica, justo é lembrar o Dr. Dennis Lo, o médico (por Oxford), investigador e professor de Patologia Qu...

